<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">37362775</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3042</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>19</Day></PubDate></JournalIssue><Title>Genes &amp; diseases</Title><ISOAbbreviation>Genes Dis</ISOAbbreviation></Journal><ArticleTitle>Microbiome and intestinal pathophysiology in post-acute sequelae of COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">100978</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gendis.2023.03.034</ELocationID><Abstract><AbstractText>Long COVID, also known for post-acute sequelae of COVID-19, describes the people who have the signs and symptoms that continue or develop after the acute COVID-19 phase. Long COVID patients suffer from an inflammation or host responses towards the virus approximately 4 weeks after initial infection with the SARS CoV-2 virus and continue for an uncharacterized duration. Anyone infected with COVID-19 before could experience long-COVID conditions, including the patients who were infected with SARS CoV-2 virus confirmed by tests and those who never knew they had an infection early. People with long COVID may experience health problems from different types and combinations of symptoms over time, such as fatigue, dyspnea, cognitive impairments, and gastrointestinal (GI) symptoms (<i>e.g.</i>, nausea, vomiting, diarrhea, decreased or loss of appetite, abdominal pain, and dysgeusia). The critical role of the microbiome in these GI symptoms and long COVID were reported in clinical patients and experimental models. Here, we provide an overall view of the critical role of the GI tract and microbiome in the development of long COVID, including the clinical GI symptoms in patients, dysbiosis, viral-microbiome interactions, barrier function, and inflammatory bowel disease patients with long COVID. We highlight the potential mechanisms and possible treatment based on GI health and microbiome. Finally, we discuss challenges and future direction in the long COVID clinic and research.</AbstractText><CopyrightInformation>&#xa9; 2023 Chongqing Medical University. Production and hosting by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jilei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois Chicago, Illinois 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yongguo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois Chicago, Illinois 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Yinglin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois Chicago, Illinois 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois Chicago, Illinois 60612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UIC Cancer Center; Department of Microbiology and Immunology, University of Illinois Chicago, Chicago, Illinois 60612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jesse Brown VA Medical Center, Chicago, Illinois 60612, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Genes Dis</MedlineTA><NlmUniqueID>101635967</NlmUniqueID><ISSNLinking>2352-3042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GI tract</Keyword><Keyword MajorTopicYN="N">Gastrointestinal symptoms</Keyword><Keyword MajorTopicYN="N">Gut microbiome</Keyword><Keyword MajorTopicYN="N">Inflammatory bowel diseases</Keyword><Keyword MajorTopicYN="N">Intestinal barrier</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Metabolites</Keyword><Keyword MajorTopicYN="N">Tight junctions</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>19</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>19</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37362775</ArticleId><ArticleId IdType="pmc">PMC10278891</ArticleId><ArticleId IdType="doi">10.1016/j.gendis.2023.03.034</ArticleId><ArticleId IdType="pii">S2352-3042(23)00223-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of covid-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136.</Citation><ArticleIdList><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M., Maralakunte M., Garg S., et al. The conundrum of &#x2018;long-COVID-19&#x2019;: a narrative review. Int J Gen Med. 2021;14:2491&#x2013;2506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214209</ArticleId><ArticleId IdType="pubmed">34163217</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Long COVID or Post-COVID Conditions. Available at https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/.</Citation></Reference><Reference><Citation>Joshee S., Vatti N., Chang C. Long-term effects of COVID-19. Mayo Clin Proc. 2022;97(3):579&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8752286</ArticleId><ArticleId IdType="pubmed">35246288</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J., Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol. 2022;32(4)</Citation><ArticleIdList><ArticleId IdType="pubmed">34888989</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T., Hittle M., Goodman S.N. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Caballero-Marcos A., Citores M.J., Alonso-Fern&#xe1;ndez R., et al. Decreased long-term severe acute respiratory syndrome coronavirus 2-specific humoral immunity in liver transplantation recipients 12 months after coronavirus disease 2019. Liver Transplant. 2022;28(6):1039&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">34919762</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf F., Fahriani M., Mamada S.S., et al. Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: a systematic review and meta-analysis. F1000Research. 2021;10:301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8171196</ArticleId><ArticleId IdType="pubmed">34131481</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S.C., Canakis A., Halvorson A.E., et al. Associations between gastrointestinal symptoms and COVID-19 severity outcomes based on a propensity score-weighted analysis of a nationwide cohort. Gastro Hep Adv. 2022;1(6):977&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9357443</ArticleId><ArticleId IdType="pubmed">35966642</ArticleId></ArticleIdList></Reference><Reference><Citation>Guti&#xe9;rrez-Castrell&#xf3;n P., Gandara-Mart&#xed; T., Abreu Y Abreu A.T., et al. Probiotic improves symptomatic and viral clearance in Covid 19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microb. 2022;14(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757475</ArticleId><ArticleId IdType="pubmed">35014600</ArticleId></ArticleIdList></Reference><Reference><Citation>Sencio V., Machelart A., Robil C., et al. Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters. Gut Microb. 2022;14(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8726722</ArticleId><ArticleId IdType="pubmed">34965194</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y., Yu F., Zhang D., et al. Dynamic alterations in the respiratory tract microbiota of patients with COVID-19 and its association with microbiota in the gut. Adv Sci. 2022;9(27)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350109</ArticleId><ArticleId IdType="pubmed">35780499</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Geng X., Tan Y., et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed Pharmacother. 2020;127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186209</ArticleId><ArticleId IdType="pubmed">32361161</ArticleId></ArticleIdList></Reference><Reference><Citation>Robba C., Battaglini D., Pelosi P., Rocco P.R.M. Multiple organ dysfunction in SARS-CoV-2:MODS-CoV-2. Expet Rev Respir Med. 2020;14(9):865&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7441756</ArticleId><ArticleId IdType="pubmed">32567404</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Garrett S., Sun J. Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. Genes Dis. 2021;8(4):385&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836435</ArticleId><ArticleId IdType="pubmed">33521210</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L., Mu M., Yang P., et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020;115(5):766&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172492</ArticleId><ArticleId IdType="pubmed">32287140</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie C., Jiang L., Huang G., et al. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int J Infect Dis. 2020;93:264&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129110</ArticleId><ArticleId IdType="pubmed">32114193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Xu H., Jiang H., et al. Clinical features and outcomes of discharged coronavirus disease 2019 patients: a prospective cohort study. QJM. 2020;113(9):657&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7313792</ArticleId><ArticleId IdType="pubmed">32442308</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne C.D., Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47&#x2013;S64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25920090</ArticleId></ArticleIdList></Reference><Reference><Citation>Milic J., Barbieri S., Gozzi L., et al. Metabolic-associated fatty liver disease is highly prevalent in the postacute COVID syndrome. Open Forum Infect Dis. 2022;9(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8826155</ArticleId><ArticleId IdType="pubmed">35146047</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B., Cassar M.P., Tunnicliffe E.M., et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021;31</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808914</ArticleId><ArticleId IdType="pubmed">33490928</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien J., Ayer T., Tapper E.B., Barbosa C., Dowd W.N., Chhatwal J. Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: a modeling study. Hepatology. 2022;75(6):1480&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015640</ArticleId><ArticleId IdType="pubmed">34878683</ArticleId></ArticleIdList></Reference><Reference><Citation>Niriella M.A., Siriwardana R.C., Perera M.T.P.R., Narasimhan G., Chan S.C., Dassanayake A.S. Challenges for liver transplantation during recovery from the COVID-19 pandemic: insights and recommendations. Transplant Proc. 2020;52(9):2601&#x2013;2606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269961</ArticleId><ArticleId IdType="pubmed">32586665</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks A.W., Priya S., Blekhman R., Bordenstein S.R. Gut microbiota diversity across ethnicities in the United States. PLoS Biol. 2018;16(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6279019</ArticleId><ArticleId IdType="pubmed">30513082</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104(34):13780&#x2013;13785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1959459</ArticleId><ArticleId IdType="pubmed">17699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T., Cai G., Qiu Y., et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012;6(2):320&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3260502</ArticleId><ArticleId IdType="pubmed">21850056</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J., Li Y., Cai Z., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">23023125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.S., Lobbestael E., Vermeire S., Sabino J., Cleynen I. Inflammatory bowel disease and Parkinson&#x2019;s disease: common pathophysiological links. Gut. 2021;70:408&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">33067333</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.G., Wu S., Yi J., et al. Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Therapeut. 2017;39(2):322&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344195</ArticleId><ArticleId IdType="pubmed">28129947</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Liu H., Lin Y., Pan J., Su J. The gut microbiota and respiratory diseases: new evidence. J Immunol Res. 2020;2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7415116</ArticleId><ArticleId IdType="pubmed">32802893</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsland B.J., Trompette A., Gollwitzer E.S. The gut-lung axis in respiratory disease. Ann Am Thorac Soc. 2015;12(Suppl 2):S150&#x2013;S156.</Citation><ArticleIdList><ArticleId IdType="pubmed">26595731</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J.A., Sanidad K.Z., Lucotti S., et al. Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection. Gut Microb. 2022;14(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348133</ArticleId><ArticleId IdType="pubmed">35915556</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Q., Lau R.I., Liu Q., Chan F.K.L., Ng S.C. Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance. Gut. 2023;72(6):1230&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">35940857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Raichon L., Venzon M., Klein J., et al. Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. Nat Commun. 2022;13(1):5926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9626559</ArticleId><ArticleId IdType="pubmed">36319618</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Mak J.W.Y., Su Q., et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71(3):544&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Haran J.P., Bradley E., Zeamer A.L., et al. Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID. JCI Insight. 2021;6(20)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8564890</ArticleId><ArticleId IdType="pubmed">34403368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Wu G., Zhao L., Wang W. Nutritional modulation of gut microbiota alleviates severe gastrointestinal symptoms in a patient with post-acute COVID-19 syndrome. mBio. 2022;13(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9040862</ArticleId><ArticleId IdType="pubmed">35254129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J., Han B., Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158(6):1518&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130192</ArticleId><ArticleId IdType="pubmed">32142785</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh Y.K., Zuo T., Lui G.C.Y., et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossini V., Tolosa-Enguis V., Frances-Cuesta C., Sanz Y. Gut microbiome and anti-viral immunity in COVID-19 [published online ahead of print, 2022 Nov 16] Crit Rev Food Sci Nutr. 2022:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">36382631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Gu S., Chen Y., et al. Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut. 2022;71(1):222&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8666823</ArticleId><ArticleId IdType="pubmed">33833065</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Zhan H., Zhang F., et al. Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge. Gastroenterology. 2020;159(4):1302&#x2013;1310.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7318920</ArticleId><ArticleId IdType="pubmed">32598884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Liu Q., Zhang F., et al. Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity. Microbiome. 2021;9(1):91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8044506</ArticleId><ArticleId IdType="pubmed">33853691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.G., Zhang A., Rauseo A.M., et al. The salivary and nasopharyngeal microbiomes are associated with SARS-CoV-2 infection and disease severity. J Med Virol. 2023;95(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9880756</ArticleId><ArticleId IdType="pubmed">36583481</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasir M., Al-Sharif H.A., Al-Subhi T., et al. Analysis of the nasopharyngeal microbiome and respiratory pathogens in COVID-19 patients from Saudi Arabia. J Infect Public Health. 2023;16(5):680&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9984237</ArticleId><ArticleId IdType="pubmed">36934642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaibani P., Viciani E., Bartoletti M., et al. The lower respiratory tract microbiome of critically ill patients with COVID-19. Sci Rep. 2021;11(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8115177</ArticleId><ArticleId IdType="pubmed">33980943</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteleone G., Pallone F., MacDonald T.T. Emerging immunological targets in inflammatory bowel disease. Curr Opin Pharmacol. 2011;11(6):640&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">22000933</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald T.T., Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307(5717):1920&#x2013;1925.</Citation><ArticleIdList><ArticleId IdType="pubmed">15790845</ArticleId></ArticleIdList></Reference><Reference><Citation>Guney C., Akar F. Epithelial and endothelial expressions of ACE2:SARS-CoV-2 entry routes. J Pharm Pharmaceut Sci. 2021;24:84&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">33626315</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi K., Godoy Brewer G., Thu Nguyen M., et al. COVID-19 and outcomes in patients with inflammatory bowel disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2022;28(8):1265&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8574492</ArticleId><ArticleId IdType="pubmed">34718595</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezzio C., Saibeni S., Variola A., et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020;69(7):1213&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">32354990</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatori S., Baldassarre F., Mossa M., Monteleone G. Long COVID in inflammatory bowel diseases. J Clin Med. 2021;10(23):5575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8658587</ArticleId><ArticleId IdType="pubmed">34884276</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A., Koch R., Jukic A., et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163(2):495&#x2013;506.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Thongtan T., Deb A., Islam S. De novo inflammatory bowel disease is a potential post-acute sequela of SARS-CoV-2 infection. Chronicles. 2021;9(41):35&#x2013;39.</Citation></Reference><Reference><Citation>Ballering A.V., van Zon S.K.R., Olde Hartman T.C., Rosmalen J.G.M., Initiative L.C.R. Persistence of somatic symptoms after COVID-19 in The Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Kang Z., Gong H., et al. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut. 2020;69:1010&#x2013;1018.</Citation></Reference><Reference><Citation>Zang R., Gomez Castro M.F., McCune B.T., et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. 2020;5(47)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7285829</ArticleId><ArticleId IdType="pubmed">32404436</ArticleId></ArticleIdList></Reference><Reference><Citation>Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Transl Res. 2020;226:57&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7438210</ArticleId><ArticleId IdType="pubmed">32827705</ArticleId></ArticleIdList></Reference><Reference><Citation>Trottein F., Sokol H. Potential causes and consequences of gastrointestinal disorders during a SARS-CoV-2 infection. Cell Rep. 2020;32(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332457</ArticleId><ArticleId IdType="pubmed">32649864</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva Andrade B., Siqueira S., de Assis Soares W.R., et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021;13(4):700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072585</ArticleId><ArticleId IdType="pubmed">33919537</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z., Song Z.G., Liu C., et al. Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients. BMC Med. 2022;20(1):24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8769945</ArticleId><ArticleId IdType="pubmed">35045853</ArticleId></ArticleIdList></Reference><Reference><Citation>Deinhardt-Emmer S., B&#xf6;ttcher S., H&#xe4;ring C., et al. SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction. J Virol. 2021;95(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139673</ArticleId><ArticleId IdType="pubmed">33637603</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron L.B., Dweep H., Yin X., et al. Plasma markers of disrupted gut permeability in severe COVID-19 patients. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8219958</ArticleId><ArticleId IdType="pubmed">34177935</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron L.B., Peluso M.J., Ding J., et al. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-&#x3ba;B signaling. JCI Insight. 2022;7(15)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9462470</ArticleId><ArticleId IdType="pubmed">35727635</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E., Xie Y., Al-Aly Z. Long-term gastrointestinal outcomes of COVID-19. Nat Commun. 2023;14:983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9992516</ArticleId><ArticleId IdType="pubmed">36882400</ArticleId></ArticleIdList></Reference><Reference><Citation>Sencio V., Gallerand A., Gomes Machado M., et al. Influenza virus infection impairs the gut's barrier properties and favors secondary enteric bacterial infection through reduced production of short-chain fatty acids. Infect Immun. 2021;89(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8370677</ArticleId><ArticleId IdType="pubmed">33820816</ArticleId></ArticleIdList></Reference><Reference><Citation>Sfera A., Osorio C., Hazan S., et al. Long COVID and the neuroendocrinology of microbial translocation outside the GI tract: some treatment strategies. Endocrine. 2022;3(4):703&#x2013;725.</Citation></Reference><Reference><Citation>Spindler K.R., Hsu T.H. Viral disruption of the blood-brain barrier. Trends Microbiol. 2012;20(6):282&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367119</ArticleId><ArticleId IdType="pubmed">22564250</ArticleId></ArticleIdList></Reference><Reference><Citation>Salina A.C.G., Dos-Santos D., Rodrigues T.S., et al. Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory functions and clearance of apoptotic cells. Elife. 2022;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9262386</ArticleId><ArticleId IdType="pubmed">35666101</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte-Schrepping J., Reusch N., Paclik D., et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182(6):1419&#x2013;1440.e23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405822</ArticleId><ArticleId IdType="pubmed">32810438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley C.P., Teng F., Felix K.M., et al. Segmented filamentous bacteria provoke lung autoimmunity by inducing gut-lung axis Th17 cells expressing dual TCRs. Cell Host Microbe. 2017;22(5):697&#x2013;704.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5749641</ArticleId><ArticleId IdType="pubmed">29120746</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley K.C., Finsterbusch K., Schnepf D., et al. Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection. Cell Rep. 2019;28(1):245&#x2013;256.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">31269444</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford M.S., Nordgren T.M., McCole D.F. Every breath you take: impacts of environmental dust exposure on intestinal barrier function-from the gut-lung axis to COVID-19. Am J Physiol Gastrointest Liver Physiol. 2021;320(4):G586&#x2013;G600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054554</ArticleId><ArticleId IdType="pubmed">33501887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau H.C.H., Ng S.C., Yu J. Targeting the gut microbiota in coronavirus disease 2019: hype or hope? Gastroenterology. 2022;162(1):9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8425294</ArticleId><ArticleId IdType="pubmed">34508775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau H.C.H., Yu J. Springer; Singapore: 2023. Gut Microbiota in Coronavirus Disease 2019. Yu J. Microbiome in Gastrointestinal Cancer; pp. 289&#x2013;302.</Citation></Reference><Reference><Citation>Romano-Keeler J., Zhang J., Sun J. COVID-19 and the neonatal microbiome: will the pandemic cost infants their microbes? Gut Microb. 2021;13(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8115548</ArticleId><ArticleId IdType="pubmed">33960272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Zhang F., Lui G.C.Y., et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159(3):944&#x2013;955.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva J.P.B., Navegantes-Lima K.C., Oliveira A.L.B., et al. Protective mechanisms of butyrate on inflammatory bowel disease. Curr Pharmaceut Des. 2018;24(35):4154&#x2013;4166.</Citation><ArticleIdList><ArticleId IdType="pubmed">30277149</ArticleId></ArticleIdList></Reference><Reference><Citation>Govindarajan N., Agis-Balboa R.C., Walter J., Sananbenesi F., Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis. 2011;26(1):187&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">21593570</ArticleId></ArticleIdList></Reference><Reference><Citation>Quraishi M.N., Widlak M., Bhala N., et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46(5):479&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">28707337</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayasinghe T.N., Chiavaroli V., Holland D.J., Cutfield W.S., O'Sullivan J.M. The new era of treatment for obesity and metabolic disorders: evidence and expectations for gut microbiome transplantation. Front Cell Infect Microbiol. 2016;6:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759265</ArticleId><ArticleId IdType="pubmed">26925392</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj J.S., Kassam Z., Fagan A., et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017;66(6):1727&#x2013;1738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6102730</ArticleId><ArticleId IdType="pubmed">28586116</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagessar S.A.R., Long C., Cui B., Zhang F. Improvement of Good's syndrome by fecal microbiota transplantation: the first case report. J Int Med Res. 2019;47(7):3408&#x2013;3415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6683929</ArticleId><ArticleId IdType="pubmed">31218940</ArticleId></ArticleIdList></Reference><Reference><Citation>Faming Zhang, The Second Hospital of Nanjing Medical University. Washed Microbiota Transplantation for Patients with 2019-nCoV Infection. Available at https://clinicaltrials.gov/ct2/show/NCT04251767?cond=NCT04251767&amp;draw=2&amp;rank=1.</Citation></Reference><Reference><Citation>Ianiro G., Mullish B.H., Kelly C.R., et al. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut. 2020;69(9):1555&#x2013;1563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456726</ArticleId><ArticleId IdType="pubmed">32620549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemian N., Kao D., Pakpour S. Fecal microbiota transplantation during and post-COVID-19 pandemic. Int J Mol Sci. 2021;22(6):3004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7998826</ArticleId><ArticleId IdType="pubmed">33809421</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V. Long COVID-19: challenges in the diagnosis and proposed diagnostic criteria. Diabetes Metabol Syndr. 2021;15(1):145&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737559</ArticleId><ArticleId IdType="pubmed">33341598</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P., Pittet L.F., Curtis N. The challenge of studying long COVID: an updated review. Pediatr Infect Dis J. 2022;41(5):424&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8997013</ArticleId><ArticleId IdType="pubmed">35213866</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacucci M., Cannatelli R., Labarile N., et al. Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. Lancet Gastroenterol Hepatol. 2020;5(6):598&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7162648</ArticleId><ArticleId IdType="pubmed">32305075</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R., Singh P.K., Kumar R., et al. Multi-omics approach in the identification of potential therapeutic biomolecule for COVID-19. Front Pharmacol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8149611</ArticleId><ArticleId IdType="pubmed">34054532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Liu Z., Chen Z., et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol. 2020;92(6):667&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228400</ArticleId><ArticleId IdType="pubmed">32167180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Lee J.Y., Yang J.S., Kim J.W., Kim V.N., Chang H. The architecture of SARS-CoV-2 transcriptome. Cell. 2020;181(4):914&#x2013;921.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179501</ArticleId><ArticleId IdType="pubmed">32330414</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D., Klann K., Koch B., et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020;583(7816):469&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">32408336</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y., Liu Y., Cao L., et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microb Infect. 2020;9(1):761&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170362</ArticleId><ArticleId IdType="pubmed">32228226</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen B., Yi X., Sun Y., et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182(1):59&#x2013;72.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7254001</ArticleId><ArticleId IdType="pubmed">32492406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P., Chen D., Ding W., et al. The trans-omics landscape of COVID-19. Nat Commun. 2021;12(1):4543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8316550</ArticleId><ArticleId IdType="pubmed">34315889</ArticleId></ArticleIdList></Reference><Reference><Citation>Millett G.A., Jones A.T., Benkeser D., et al. Assessing differential impacts of COVID-19 on black communities. Ann Epidemiol. 2020;47:37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224670</ArticleId><ArticleId IdType="pubmed">32419766</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandler R., Guillaume D., Parker A.G., et al. The impact of COVID-19 among Black women: evaluating perspectives and sources of information. Ethn Health. 2021;26(1):80&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542278</ArticleId><ArticleId IdType="pubmed">33153287</ArticleId></ArticleIdList></Reference><Reference><Citation>Rushovich T., Boulicault M., Chen J.T., et al. Sex disparities in COVID-19 mortality vary across US racial groups. J Gen Intern Med. 2021;36(6):1696&#x2013;1701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8020825</ArticleId><ArticleId IdType="pubmed">33818679</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Nearly One in Five American Adults Who Have Had COVID-19 Still Have &#x201c;Long COVID&#x201d;. Available at https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm (accessed October 15).</Citation></Reference><Reference><Citation>Romano-Keeler J., Fiszbein D., Zhang J., et al. Center-based experiences implementing strategies to reduce risk of horizontal transmission of SARS-cov-2: potential for compromise of neonatal microbiome assemblage. medRxiv. 2021;2021</Citation></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz Y.M.J., Van Herck M., Delbressine J.M., et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):542&#x2013;2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E., Janvier P., Kherabi Y., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4&#x2013;e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q., Xu M., Li J., et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C., Laurent E., Lemaignen A., et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27(2):258&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellai M., O'Keefe J.B. Characterization of prolonged COVID-19 symptoms in an outpatient telemedicine clinic. Open Forum Infect Dis. 2020;7(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543492</ArticleId><ArticleId IdType="pubmed">33117851</ArticleId></ArticleIdList></Reference><Reference><Citation>Daher A., Balfanz P., Cornelissen C., et al. Follow up of patients with severe coronavirus disease 2019 (COVID-19): pulmonary and extrapulmonary disease sequelae. Respir Med. 2020;174</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7573668</ArticleId><ArticleId IdType="pubmed">33120193</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, march-june 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Eiros R., Barreiro-P&#xe9;rez M., Mart&#xed;n-Garc&#xed;a A., et al. Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional descriptive study in healthcare workers. Rev Esp Cardiol. 2022;75(9):734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8570413</ArticleId><ArticleId IdType="pubmed">34866030</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng J., Li Y., Li J., et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. Lancet Gastroenterol Hepatol. 2021;6(5):344&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7943402</ArticleId><ArticleId IdType="pubmed">33711290</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Mart&#xed;n-Guerrero J., Navarro-Pardo E., Torres-Macho J., Canto-Diez M.G., Pellicer-Valero O. Gastrointestinal symptoms at the acute COVID-19 phase are risk factors for developing gastrointestinal post-COVID symptoms: a multicenter study. Intern Emerg Med. 2022;17(2):583&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8505473</ArticleId><ArticleId IdType="pubmed">34637081</ArticleId></ArticleIdList></Reference><Reference><Citation>Newsome R.C., Gauthier J., Hernandez M.C., et al. The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort. Gut Microb. 2021;13(1):1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8205023</ArticleId><ArticleId IdType="pubmed">34100340</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Zhang W., Guo M., et al. Integrated analysis of gut microbiome and host immune responses in COVID-19. Front Med. 2022;16(2):263&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8902486</ArticleId><ArticleId IdType="pubmed">35258762</ArticleId></ArticleIdList></Reference><Reference><Citation>Romani L., Del Chierico F., Macari G., et al. The relationship between pediatric gut microbiota and SARS-CoV-2 infection. Front Cell Infect Microbiol. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9304937</ArticleId><ArticleId IdType="pubmed">35873161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z., Wang H., Cui G., et al. Alterations in the human oral and gut microbiomes and lipidomics in COVID-19. Gut. 2021;70(7):1253&#x2013;1265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8042598</ArticleId><ArticleId IdType="pubmed">33789966</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrich W.C., Ghosh T.S., Ahearn-Ford S., et al. A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2. Gut Microb. 2022;14(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9116414</ArticleId><ArticleId IdType="pubmed">35574937</ArticleId></ArticleIdList></Reference><Reference><Citation>Schult D., Reitmeier S., Koyumdzhieva P., et al. Gut bacterial dysbiosis and instability is associated with the onset of complications and mortality in COVID-19. Gut Microb. 2022;14(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8855857</ArticleId><ArticleId IdType="pubmed">35174781</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., Zhou M., Dong X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata N., Takeuchi T., Masuoka H., et al. Human gut microbiota and its metabolites impact immune responses in COVID-19 and its complications. Gastroenterology. 2023;164(2):272&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9499989</ArticleId><ArticleId IdType="pubmed">36155191</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Emran H.M., Rahman S., Hasan M.S., et al. Microbiome analysis revealing microbial interactions and secondary bacterial infections in COVID-19 patients comorbidly affected by type 2 diabetes. J Med Virol. 2023;95(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9874868</ArticleId><ArticleId IdType="pubmed">36258280</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma&#x144;kowska-Wierzbicka D., Zuraszek J., Wierzbicka A., et al. Alterations in gut microbiota composition in patients with COVID-19: a pilot study of whole hypervariable 16S rRNA gene sequencing. Biomedicines. 2023;11(2):367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9953267</ArticleId><ArticleId IdType="pubmed">36830905</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>